- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06854640
Safe Bay 3389934가 얼마나 적합한 지, 적절한 복용량 및 패혈증 유발 응고 병증에 미치는 영향에 대한 연구.
먼저 환자, 용량 에스컬레이션, 오픈 라벨 연구는 패혈증 유발 응고 병증 환자에 대한 베이 3389934의 정맥 내 주입의 안전성, 내약성, 약동학 및 약력학을 조사하기위한 오픈 라벨 연구
Researchers are looking for a better way to treat people who have sepsis induced coagulopathy.
Sepsis happens when bacteria and their toxins spread in the blood, causing an infection. To overcome the infection the body responds activating the immune system, sometimes this immune response is too active and causes uncontrolled blood clot formation, also called sepsis-induced coagulopathy. Sepsis coagulopathy damages blood vessels and organs and leads to low platelet levels in the body. In severe cases, it can even lead to death.
The main purpose of this first in patient study is to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis induced coagulopathy. For this study, researchers will enroll people receiving treatment for sepsis induced coagulopathy in a hospital intensive care unit (ICU).
For this, the researchers will collect the number of participants with medical problems during and after receiving BAY 3389934. These medical problems are also known as "adverse events". Doctors keep track of all medical problems that happen in studies, even if they do not think they might be related to the study treatments.
Participants will be divided into 2 groups. The first group will receive the lowest starting dose of BAY3389934. The researcher will carefully monitor how the participant responds to the medication and may adjust the dose, either increasing or decreasing it based on the safety and the tolerability of the drug. If no serious side effects are reported from the first group, the second group will receive higher dose of BAY3389934.
Each participant will be in the study for around 28 days. During the study, the doctors and their study team will:
- Take blood and urine samples,
- Do physical examinations,
- Check vital signs such as body temperature, blood pressure and heart rate,
- Examine heart health using electrocardiogram (ECG)
연구 개요
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Bayer Clinical Trials Contact
- 전화번호: 188884229
- 이메일: clinical-trials-contact@bayer.com
연구 장소
-
-
Gelderland
-
Nijmegen, Gelderland, 네덜란드, 6525 GA
- 아직 모집하지 않음
- Universitair Medisch Centrum St. Radboud - Intensive Care
-
Nijmegen, Gelderland, 네덜란드, 6532 SZ
- 아직 모집하지 않음
- Canisius WIlhelmina Ziekenhuis - Intensive Care
-
-
North Brabant
-
's-Hertogenbosch, North Brabant, 네덜란드, 5223 GZ
- 아직 모집하지 않음
- Jeroen Bosch Ziekenhuis - Intensive Care
-
-
Overijssel
-
Enschede, Overijssel, 네덜란드, 7512 KZ
- 아직 모집하지 않음
- Medisch Spectrum Twente - Intensive Care
-
-
South Holland
-
Rotterdam, South Holland, 네덜란드, 3015 GD
- 아직 모집하지 않음
- Erasmus Medisch Centrum - Intensive Care
-
-
-
-
Bavaria
-
München, Bavaria, 독일, 81377
- 아직 모집하지 않음
- Klinikum der Universität München AöR - Klinik für Anaesthesiologie (Campus Großhadern)
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, 독일, 51109
- 아직 모집하지 않음
- Kliniken der Stadt Köln gGmbH - Krankenhaus Merheim - Lungenklinik
-
-
Saxony
-
Dresden, Saxony, 독일, 01307
- 모병
- Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden | Medizinische Klinik I - FB Haemostaseologie
-
Leipzig, Saxony, 독일, 04103
- 아직 모집하지 않음
- Universitätsklinikum Leipzig AöR_Interdisziplinare Internistische Intensivmedizin
-
-
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 아직 모집하지 않음
- UC Health University of Colorado Hospital - Medical Intensive Care Unit
-
-
-
-
-
Liège, 벨기에, 4000
- 모병
- Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Intensive Care
-
-
Antwerp
-
Edegem, Antwerp, 벨기에, 2650
- 아직 모집하지 않음
- UZ Antwerpen - Intensive Care
-
-
Brussels Capital
-
Woluwe-Saint-Lambert, Brussels Capital, 벨기에, 1200
- 아직 모집하지 않음
- Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc - Intensive Care
-
-
Walloon Brabant
-
Ottignies, Walloon Brabant, 벨기에, 1340
- 모병
- Clinique Saint-Pierre d'Ottignies - Intensive Care
-
-
-
-
Centre-Val de Loire
-
Tours, Centre-Val de Loire, 프랑스, 37044
- 아직 모집하지 않음
- CHRU de Tours - Hôpital Bretonneau - Médecine Intensive Réanimation
-
-
Grand Est
-
Strasbourg, Grand Est, 프랑스, 67091
- 모병
- Hopitaux Universitaires de Strasbourg Nouvel Hopital Civil - Service de Médecine Intensive Réanimation
-
-
New Aquitaine
-
Limoges, New Aquitaine, 프랑스, 87042
- 모병
- Centre Hospitalier Universitaire de Limoges Dupuytren 1 - Service de réanimation polyvalente
-
-
Pays de la Loire Region
-
Angers, Pays de la Loire Region, 프랑스, 49100
- 모병
- Centre Hospitalier Universitaire d'Angers - Médecine Intensive Réanimation et Médecine Hyperbare
-
La Roche-sur-Yon, Pays de la Loire Region, 프랑스, 85000
- 모병
- Centre Hospitalier Départemental Vendée - Service de réanimation polyvalente
-
Nantes, Pays de la Loire Region, 프랑스, 44000
- 모병
- Hopital Hotel Dieu Nantes - Service de Médecine Intensive Réanimation
-
-
Île-de-France Region
-
Garches, Île-de-France Region, 프랑스, 92380
- 아직 모집하지 않음
- Hôpital Raymond-Poincaré - Service de Médecine Intensive - Réanimation, Médecine Hyperbare
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Participant must be ≥ 18 and ≤ 85 years of age at the time of signing the informed consent.
- Participants with diagnosed sepsis according to sepsis-3 criteria. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.
- participants with suspected or documented origin of infection.
- Participants with coagulopathy defined by at least one of the following within 24 hours prior start of study intervention: INR ≥1.40, platelet count in the range of ≥ 30,000/mm3 to < 150,000/mm3 OR greater than 30% decrease in platelets in 24 hours without other known etiology. The platelet count after decrease should not be < 30,000/mm3.
- Participants must be receiving treatment in an ICU.
- Informed consent of capable participant or, in case of participant being incapable of giving informed consent, consent for study inclusion will be sought according to applicable laws and regulations.
Exclusion Criteria:
-
Clinically significant active bleeding; known bleeding disorder, history of major traumatic or non-traumatic bleeding (intracranial, retroperitoneal, intraocular) or clinically significant gastrointestinal bleeding within last 6 months.
-
Low platelets level or abnormal coagulation status due to any other reason than sepsis.
-
Participants with indication for therapeutic dose of: anticoagulation (heparin, argatroban, vitamin K antagonists/warfarin, dabigatran, apixaban, rivaroxaban, edoxaban), oral antiplatelet agents (clopidogrel, ticagrelor, ticlopidine, prasugrel) except low dose (≤100mg) acetyl salicylic acid (ASA), digoxin, metformin
-
Participants with:
- Uncontrolled malignancy requiring ongoing chemotherapy, radiation therapy, or immunotherapy within the past 6 months with the exception of: low-risk localized prostate cancer (Gleason score is equal to or less than 6 AND Prostate- Specific Antigen is below 10 ng/mL); or cervical carcinoma in situ; or ductal carcinoma in situ; or adequately treated non-metastatic squamous cell skin carcinoma; or adequately treated basal cell skin carcinoma. Patients with breast or prostate cancer receiving single endocrine (hormonal) therapy are eligible if all other cancer-directed treatments were completed more than 6 months prior to screening
- Any hematological malignancy
- Any active or prior malignancy involving the central nervous system (brain or spinal cord), including primary tumors or metastases.
-
Pregnancy or breastfeeding.
-
Chronic liver disease Child-Pugh Class C.
-
Participants experienced major surgery or major trauma (intrathoracic, intra-abdominal, pelvic or femur) or surgery/trauma in any other area with potentially clinically significant consequences due to bleeding within 28 days before study drug administration.
-
Participants experienced neurotrauma or neurosurgery (brain, spine) or orthopedic surgery in spine within 6 months before study drug administration
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Cohort 1 of BAY3389934
Subjects will receive titrated dose of BAY3389934 as continuous infusion over up to 96 hours. |
Solution for IV infusion |
|
실험적: Cohort 2 of BAY3389934
Subjects will receive titrated dose of BAY3389934 as continuous infusion over up to 96 hours. |
Solution for IV infusion |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Teaes의 참가자 수 (치료 부작용)
기간: 연구 중재 중단 후 1 시간까지의 연구 중재의 첫 번째 투여 후, 최대 97 시간
|
연구 중재 중단 후 1 시간까지의 연구 중재의 첫 번째 투여 후, 최대 97 시간
|
|
차의 심각성
기간: 연구 중재 중단 후 1 시간까지의 연구 중재의 첫 번째 투여 후, 최대 97 시간
|
연구 중재 중단 후 1 시간까지의 연구 중재의 첫 번째 투여 후, 최대 97 시간
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
활성화 된 부분 트롬 보플 라스틴 시간 (APTT)
기간: 연구 중재의 첫 번째 투여에서 1 일까지 6 일까지
|
연구 중재의 첫 번째 투여에서 1 일까지 6 일까지
|
|
Prothrombin Time (PT)
기간: 연구 중재의 첫 번째 투여에서 1 일까지 6 일까지
|
연구 중재의 첫 번째 투여에서 1 일까지 6 일까지
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 22265
- 2024-515635-30-00 (레지스트리 식별자: CTIS (EU))
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .